Showing 981-990 of 1317 results for "".
Cosmeceuticals: A Clinician's Guide to Science, Selection, Marketing, and Dispensing
https://practicaldermatology.com/topics/general-topics/cosmeceuticals-a-clinicians-guide-to-science-selection-marketing-and-dispensing/22007/Experienced physicians describe dispensing strategies that provide the greatest benefit to the patient and the practice.Medical Dermatology Myths
https://practicaldermatology.com/topics/general-topics/medical-dermatology-myths/22036/Here are the facts about seven common misconceptions that may hinder effective patient care.Business Advisor: Mapping Out a Price/Benefit Value Strategy for Your Practice
https://practicaldermatology.com/topics/general-topics/business-advisor-mapping-out-a-pricebenefit-value-strategy-for-your-practice/22043/Using a Price/Benefit map is a good way for practices to set prices and plan to adapt to changing markets.A Review of Complications of Biologic Therapy for Psoriasis
https://practicaldermatology.com/topics/general-topics/1109_02-php/22053/Therapeutic success requires clinicians to understand emerging and established safety concerns.Expanding the Field: A New Botulinum Neurotoxin A Enters The US Arena
https://practicaldermatology.com/topics/general-topics/PD0609_07-php/22816/A cosmetic dermatologist with experience using Dysport describes how clinicians may approach the new agent in practice.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muCutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuDermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldWhat (More) Do You Want From Me? Reflections on Mentorship, Dermatology, and Moving Forward
https://practicaldermatology.com/issues/september-2025/what-more-do-you-want-from-me-reflections-on-mentorship-dermatology-and-moving-forward/37625/Professionally and personally, it’s hard to avoid the “what if” and “if only” scenarios. But when those thoughts outweigh the pride in where we’ve landed or who we’ve become, maybe it’s time to pause and appreciate the labor and sacrifices that got us here.First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.